Francois Brisebois
Stock Analyst at Oppenheimer
(1.66)
# 3,454
Out of 5,239 analysts
75
Total ratings
36%
Success rate
-2%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRDA Entrada Therapeutics | Maintains: Outperform | $21 → $23 | $7.12 | +223.03% | 3 | Apr 6, 2026 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $95 → $105 | $59.83 | +75.50% | 8 | Feb 25, 2026 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $7 → $8 | $4.16 | +92.31% | 3 | Sep 8, 2025 | |
| SVRA Savara | Maintains: Outperform | $5 → $6 | $5.08 | +18.11% | 6 | Aug 15, 2025 | |
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $70 → $80 | $21.00 | +280.95% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $5.68 | +181.69% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $2.87 | +39.37% | 1 | Jan 29, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $59 → $61 | $30.15 | +102.32% | 6 | Jan 13, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $143 → $163 | $343.20 | -52.51% | 4 | Oct 31, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $55 | $18.37 | +199.40% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $3.12 | +380.77% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $6.33 | -5.21% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $5.99 | +83.64% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $39.61 | -64.66% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $13.96 | +365.62% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.71 | +484.80% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $16.13 | +123.19% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $2,500 → $1,500 | $2.56 | +58,493.75% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $1.26 | +428,471.43% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $1.69 | +550.89% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $1.87 | +862.57% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $9.37 | +433.62% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $0.59 | +553,746.15% | 1 | Feb 4, 2020 |
Entrada Therapeutics
Apr 6, 2026
Maintains: Outperform
Price Target: $21 → $23
Current: $7.12
Upside: +223.03%
Tarsus Pharmaceuticals
Feb 25, 2026
Maintains: Outperform
Price Target: $95 → $105
Current: $59.83
Upside: +75.50%
Aquestive Therapeutics
Sep 8, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $4.16
Upside: +92.31%
Savara
Aug 15, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $5.08
Upside: +18.11%
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $21.00
Upside: +280.95%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $5.68
Upside: +181.69%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $2.87
Upside: +39.37%
Harmony Biosciences Holdings
Jan 13, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $30.15
Upside: +102.32%
Praxis Precision Medicines
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $343.20
Upside: -52.51%
Dyne Therapeutics
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $18.37
Upside: +199.40%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $3.12
Upside: +380.77%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $6.33
Upside: -5.21%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $5.99
Upside: +83.64%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $39.61
Upside: -64.66%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $13.96
Upside: +365.62%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.71
Upside: +484.80%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $16.13
Upside: +123.19%
Apr 3, 2023
Maintains: Outperform
Price Target: $2,500 → $1,500
Current: $2.56
Upside: +58,493.75%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $1.26
Upside: +428,471.43%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $1.69
Upside: +550.89%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $1.87
Upside: +862.57%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $9.37
Upside: +433.62%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $0.59
Upside: +553,746.15%